• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Immunotherapy

Terumo launches therapeutic interventional oncology team

April 13, 2021 By Sean Whooley

Terumo

Terumo (TSE: 4543) announced that it has launched a global therapeutic interventional oncology team, effective April 1, 2021. Leuven, Belgium-based Terumo said in a news release that team’s introduction reflects its aspiration to be a global leader in the interventional oncology space by focusing on improving quality of life and survival. Team members work in […]

Filed Under: Business/Financial News, Drug-Device Combinations, Featured, Immunotherapy, Oncology, Pharmaceuticals Tagged With: Terumo Corp.

TriSalus, University of Texas to collaborate on solid tumor treatment study

April 8, 2021 By Sean Whooley

TriSalus-logo

TriSalus Life Sciences and the University of Texas today announced a collaboration to evaluate the treatment of solid tumors. The Texas MD Anderson Cancer Center and TriSalus will collaborate on treatments for tumors of the pancreas and liver by integrating interventional delivery of SD-101, an investigational toll-like receptor 9 (TLR9) agonist, in combination with checkpoint […]

Filed Under: Business/Financial News, Clinical Trials, Drug-Device Combinations, Featured, Immunotherapy, Oncology Tagged With: trisaluslifesciences, University of Texas MD Anderson Cancer Center

UroGen Pharma raises $75M

March 18, 2021 By Sean Whooley

UroGen Pharma

UroGen Pharma (NSDQ:URGN) announced today that it entered into a funding agreement with RTW Investments worth $75 million. Princeton, N.J.-based UroGen’s agreement with RTW will see the biopharmaceutical company receive $75 million in upfront cash in return for tiered, future cash payments based on aggregate worldwide annual net product sales of Jelmyto (mitomycin) for pyelocalyceal […]

Filed Under: Business/Financial News, Drug-Device Combinations, Featured, Funding Roundup, Hydrogels, Immunotherapy Tagged With: UroGen Pharma

Bicara Therapeutics launches with $40M investment

March 15, 2021 By Sean Whooley

Bicara Therapeutics

Bicara Therapeutics announced today that it has launched with a $40 million investment from Biocon Limited. Cambridge, Mass.-based Bicara’s financing is earmarked for the advancement of its pipeline of first-in-class bifunctional antibodies developed between an engineering team in Bangalore, India, and the Cambridge-based executive team, according to a news release. Bicara’s pipeline includes tumor-targeted antibodies […]

Filed Under: Business/Financial News, Drug-Device Combinations, Featured, Funding Roundup, Immunotherapy, Oncology, Pharmaceuticals Tagged With: Bicara Therapeutics, biocon

Takeda to acquire T-cell engager therapy maker Maverick Therapeutics for $525M

March 10, 2021 By Sean Whooley

Takeda Maverick Therapeutics

Takeda Pharmaceutical (NYSE:TAK) announced that it is acquiring Maverick Therapeutics in a deal worth up to $525 million. Osaka, Japan-based Takeda exercised its option to acquire Maverick and its T-cell engager Cobra platform and development portfolio, including multiple solid tumor treatments in various clinical stages. Following the closing of the deal, Maverick employees will join […]

Filed Under: Business/Financial News, Drug-Device Combinations, Featured, Immunotherapy, Mergers & Acquisitions, Oncology, Pharmaceuticals Tagged With: Maverick Therapeutics, Takeda Pharmaceutical Co

Janux Therapeutics raises $56M Series A for T cell engager tech

March 3, 2021 By Sean Whooley

Janux Therapeutics

Janux Therapuetics announced today that it closed a $56 million Series A financing as it develops its T cell engager technology. Avalon Ventures led the financing round, while new investors OrbiMed and RA Capital Management joined in. Additionally, existing investors Bregua and Correlation Ventures participated. OrbiMed partner Dr. Peter Thompson and RA Capital Management partner […]

Filed Under: Business/Financial News, Drug-Device Combinations, Featured, Funding Roundup, Immunotherapy, Oncology, Pharmaceuticals Tagged With: Janux Therapeutics

OncoSec announces positive results in metastatic melanoma case study

December 4, 2020 By Brian Buntz

Oncosec

The International Journal of Surgery Case Reports has published a case study on the use of the humanized antibody Keytruda (pembrolizumab) and tavokinogene telseplasmid (TAVO) from OncoSec (NSDQ:ONCS) for treating metastatic melanoma. The study involved a patient with stage IIB, pT3b melanoma who initially underwent tumor resection but experienced regional recurrence and later disease progression […]

Filed Under: Immunotherapy, Oncology, Surgical Tagged With: electroporation, Keytruda, melanoma, Oncosec, pembrolizumab, TAVO, tavokinogene telseplasmid

Inovio to scale up production of smart delivery device for potential COVID-19 vaccine

July 24, 2020 By Sean Whooley

Inovio Pharma

Inovio Pharmaceuticals (NSDQ:INO) announced that it received $71 million from the U.S. Defense Dept. to support its Cellectra 3PSP smart device. Funding from the DoD is set to support large-scale manufacturing for the Cellectra 3PSP and the procurement of Cellectra 2000 devices, which are used to deliver Inovio’s INO-4800 COVID-19 vaccine candidate directly into the skin. […]

Filed Under: Business/Financial News, Clinical Trials, Drug-Device Combinations, Featured, Funding Roundup, Immunotherapy Tagged With: coronavirus, COVID-19, Inovio Pharmaceuticals, U.S. Defense Dept.

MIT researchers think they’ve found a way to get more particles through a syringe

July 8, 2020 By Sean Whooley

Researchers at the Massachusetts Institute of Technology (MIT) are touting a computational model that could prevent microparticle clogging during injections. Microparticles, which are about the size of a grain of sand, can be difficult to inject if they get clogged in a typical syringe. The research team at MIT developed this new model that determines […]

Filed Under: Discovery, Drug-Device Combinations, Featured, Immunotherapy, Research & Development Tagged With: Massachusetts Institute of Technology

AbbVie gains U.S. nod for $63B Allergan takeover

May 6, 2020 By Nancy Crotti

Pharmaceutical giant  AbbVie (NYSE:ABBV) has won U.S. antitrust approval for its  purchase of Allergan (NYSE:AGN) for $63 billion in cash and stock. The purchase is seen as a hedge against the impending expiration of U.S. patents on AbbVie’s blockbuster drug, Humira. North Chicago-based AbbVie announced the deal in June 2019, but ran up against U.S. Federal Trade Commission […]

Filed Under: Business/Financial News, Featured, Immunotherapy, Pharmaceuticals, Wall Street Beat Tagged With: AbbVie, Allergan, AstraZeneca plc, Federal Trade Commission (FTC), Johnson & Johnson

  • Go to page 1
  • Go to page 2
  • Go to page 3
  • Interim pages omitted …
  • Go to page 7
  • Go to Next Page »

Primary Sidebar

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Need Drug Delivery Business News in a minute? We Deliver!
Drug Delivery Enewsletters get you caught up on all the mission critical news you need in med tech. Sign up today.

Footer

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Design & Outsourcing
Medical Tubing + Extrusion

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery News
Advertise with us
About
Contact us
Privacy
Add us on FacebookFollow us on TwitterConnect with us on LinkedIn

Copyright © 2021 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Advertise | Privacy Policy | RSS